about
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cellsMultikinase inhibitors use in differentiated thyroid carcinoma.Modeling follicular thyroid cancer for future therapiesBinimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway InhibitorsSignal transduction via the T cell antigen receptor in naïve and effector/memory T cells.Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation.Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.Substituted 3-benzylcoumarins as allosteric MEK1 inhibitors: design, synthesis and biological evaluation as antiviral agents.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.MEK inhibitors in oncology: a patent review (2015-Present).The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.
P2860
Q27853084-41448876-6E62-4681-98B2-6BF96A471698Q28484496-82FE2294-7FDC-4BE0-A9A0-45073947D3F0Q34660901-93A2AA33-C9D7-4EF7-AB5B-3011CB27FA9EQ35832908-95670ED3-27A9-4E0B-8A14-A1B6BE9A8263Q35939402-0FF406B8-50B1-4AE0-815C-5C72B5C162C3Q36257295-4E2A3F80-95C4-4E65-A4FE-41C64CA38DAAQ36495930-54908FF0-11F9-4954-BE73-56C0BF3963C7Q36985669-945E7A81-8209-4FC8-8796-5D176016D66BQ37715539-EDC7A109-C3CF-4EF2-B60A-BEB759044684Q37976467-BCF22C55-1EBE-43D8-BF4C-8FA8F0E89FF2Q38046230-CC5D3E4E-23B9-4426-A267-5A218466E44CQ38053855-0619AFA5-91BB-4C87-8BF9-36D8646617FFQ38162917-0023FEC8-C7C7-43B4-99D0-DDCB59A08FB6Q38217595-AD8024F9-0013-4EC4-BF2B-BDA9619404ADQ39148610-7E320841-7A4B-4CB5-B138-3FF8E254384FQ39270291-2572AA51-43AC-45B7-B7F1-33D586605392Q39359514-70BEF750-5583-4D53-828E-1F2D0D513CBCQ43239778-FFB30621-93AA-4B71-AB4E-D9D95A3CE12D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MEK inhibitors: a patent review 2008 - 2010.
@en
MEK inhibitors: a patent review 2008 - 2010.
@nl
type
label
MEK inhibitors: a patent review 2008 - 2010.
@en
MEK inhibitors: a patent review 2008 - 2010.
@nl
prefLabel
MEK inhibitors: a patent review 2008 - 2010.
@en
MEK inhibitors: a patent review 2008 - 2010.
@nl
P2860
P1476
MEK inhibitors: a patent review 2008 - 2010.
@en
P2093
John I Trujillo
P2860
P304
P356
10.1517/13543776.2011.577068
P407
P577
2011-05-09T00:00:00Z